Details of the Drug Combination

General Information of Drug Combination (ID: DCU7KJB)

• Drug Combination Name: ONC201 + JQ1
• Indication: Diffuse intrinsic pontine glioma; Status: Investigative [1]
• Component Drugs:
  ONC201 (DMM5SCF): N.A.
  JQ1 (DM3XQDH): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: DIPG25
  Zero Interaction Potency (ZIP) Score: 13.205
  Bliss Independence Score: 12.291
  Loewe Additivity Score: 0.472
  LHighest Single Agent (HSA) Score: 2.865

Molecular Interaction Atlas of This Drug Combination

Indication(s) of ONC201

Disease Entry	ICD 11	Status	REF
Endometrial cancer	2C76	Phase 2	[2]
Glioma	2A00.0	Phase 2	[2]
Multiple myeloma	2A83	Phase 2	[2]
Neuroendocrine cancer	2B72.1	Phase 2	[2]
Recurring respiratory infection	CA07-CA45	Phase 2	[2]
leukaemia	2A60-2B33	Phase 1/2	[2]
Lymphoma	2A80-2A86	Phase 1/2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

ONC201 Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Antagonist	[2]
Dopamine receptor (DR)	TTWFZ1N	NOUNIPROTAC	Antagonist	[4]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[2]

Indication(s) of JQ1

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[3]

JQ1 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
HUMAN bromodomain-containing protein 2 (BRD2)	TTNISW6	BRD2_HUMAN	Inhibitor	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Uncovering the Role of BRD2 in COVID-19. 2020-03-19
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)